FrancophonIA/ELRC3.0 huggingface dataset:
English: For the indication “ancillary treatment of intermittent claudication in symptomatic peripheral arterial occlusive disease (PAOD Stage II)” no data were submitted and as a result was considered as unsupported by the CHMP.
Estonian: Näidustuse „vahelduva lonkamise täiendav ravi sümptomaatilise perifeersete arterite oklusiivse haiguse korral (PAOD II staadium)” jaoks andmeid ei esitatud ja seetõttu inimravimite komitee ei toetanud seda.
English: Based on the clinical experience the group considered that no special population exists that could benefit from the treatment with this active substance in the prophylaxis of migraine headache.
Estonian: Kliinilise kogemuse alusel leidis rühm, et puudub eripopulatsioon, kes saaks migreeni profülaktikas ravist selle toimeainega kasu.
English: The CHMP concluded that, as result, no conclusion on efficacy of nicergoline as “symptomatic treatment of chronic pathological cognitive and neurosensorial impairment in elderly (excluding Alzheimer's disease and other dementia)” can be drawn from the data provided.
Estonian: Inimravimite komitee otsustas, et selle tulemusena ei saa esitatud andmetest teha järeldusi nikergoliini efektiivsuse kohta „kroonilise patoloogilise kognitiivse ja neurosensoorse häire sümptomaatilises ravis eakatel patsientidel (välja arvatud Alzheimeri tõbi ja muu dementsus)”.
English: Regarding ergotism, there were no cases identified in the MAH's safety database reporting the preferred term ergotism associated with nicergoline.
Estonian: Ergotismi osas ei olnud müügiloa hoidja ohutusandmebaasis teatatud nikergoliiniga seotud eelisterminist ergotismist.
English: The population was old and suffered from intermittent claudication.
Estonian: Populatsioon oli eakas ja patsientidel esines vahelduv lonkamine.
English: The MAHs considers that the most comprehensive review of nicergoline efficacy was completed in a meta-analysis performed in 2008 by Winblad et al.
Estonian: Müügiloa hoidja leiab, et nikergoliini efektiivsuse kõige ulatuslikum ülevaade on Windblad et al. 2008 metaanalüüsis.
English: Four cases of fibrotic events were excluded from the analysis.
Estonian: Analüüsist jäeti välja 4 fibrootilise ilmingu juhtu.
English: • Symptomatic treatment of chronic pathological cognitive and neurosensorial impairment in elderly
Estonian: • kroonilise patoloogilise kognitiivse ja neurosensoorse häire sümptomaatiline ravi eakatel patsientidel
English: • Symptomatic treatment of veno-lymphatic insufficiency
Estonian: • venolümfaatilise puudulikkuse sümptomaatiline ravi.
English: − Is not favourable for ancillary treatment of intermittent claudication in symptomatic peripheral arterial occlusive disease (PAOD Stage II).
Estonian: − ei ole soodne vahelduva lonkamise täiendava ravi korral sümptomaatilise perifeersete arterite oklusiivse haiguse korral (PAOD II staadium),
English: These data were considered insufficient by the CHMP to conclude on a beneficial efficacy of nicergoline in the prophylaxis of migraine headache.
Estonian: Inimravimite komitee pidas neid andmeid ebapiisavaks, et teha järeldusi nikergoliini efektiivsuse kohta migreeni profülaktikas.
English: The relationship between fibrosis and serotoninergic receptor activation, particularly 5-HT2B receptors by ergot derivatives is extensively described in the literature.
Estonian: Kirjanduses on ulatuslikult kirjeldatud seost fibroosi ja serotoniinergiliste retseptorite, eriti 5-HT2B retseptorite aktiveerimise vahel tungaltera derivaatide poolt.
English: − Ancillary treatment of intermittent claudication in symptomatic peripheral arterial occlusive disease (PAOD Stage II).
Estonian: − vahelduva lonkamise täiendav ravi sümptomaatilise perifeersete arterite oklusiivse haiguse korral (PAOD II staadium),
English: − Acute retinopathies of vascular origin.
Estonian: − vaskulaarse päritoluga ägedate retinopaatiate ravi,
English: Fourty (40) patients with migraine were assessed in an open clinical study that became available after the initial marketing authorisation was granted (Prusinski, Wiad.Lek, 1984).
Estonian: Avatud kliinilises uuringus, mis avaldati pärast esmase müügiloa andmist (Prusinski, Wiad.
English: • Acute retinopathies of vascular origin
Estonian: • vaskulaarse päritoluga ägedate retinopaatiate ravi,
English: − Is not favourable for ancillary treatment of Raynaud's syndrome.
Estonian: − ei ole soodne Raynaud' sündroomi täiendava ravi korral,
English: − Is not favourable for acute retinopathies of vascular origin.
Estonian: − ei ole soodne vaskulaarse päritoluga ägedate retinopaatiate korral,
English: − Is not favourable for ancillary treatment of visual acuity decrease and visual field disturbances presumably of vascular origin.
Estonian: − ei ole soodne eeldatava vaskulaarse päritoluga nägemisteravuse vähenemise ja nägemisvälja häirete täiendava ravi korral,
English: − Symptomatic treatment of chronic pathological cognitive and neurosensorial impairment in elderly (excluding Alzheimer's disease and other dementia).
Estonian: • kroonilise patoloogilise kognitiivse ja neurosensoorse häire sümptomaatiline ravi eakatel patsientidel (välja arvatud Alzheimeri tõbi ja muu dementsus),
English: − Is not favourable for symptomatic treatment of chronic pathological cognitive and neurosensorial impairment in elderly (excluding Alzheimer's disease and other dementia).
Estonian: − ei ole soodne kroonilise patoloogilise kognitiivse ja neurosensoorse häire sümptomaatilise ravi korral eakatel patsientidel (välja arvatud Alzheimeri tõbi ja muu dementsus),
English: • Ancillary treatment of visual acuity decrease and visual field disturbances presumably of vascular origin
Estonian: • eeldatava vaskulaarse päritoluga nägemisteravuse vähenemise ja nägemisvälja häirete täiendav ravi,
English: • The suspension of the marketing authorisation for nicergoline containing medicinal products referred to in Annex I in the event that no other indications are approved as part of their marketing authorisation.
Estonian: • peatada I lisas märgitud nikergoliini sisaldavate ravimite müügiluba, kui osana nende müügiloast ei ole heaks kiidetud muid näidustusi; müügiloa kehtivuse taastamiseks peab müügiloa hoidja tuvastama spetsiifilise patsientide populatsiooni, kelle jaoks ravimi kasulikkus ületab riski.
English: On the efficacy side for the indication “symptomatic treatment of chronic pathological cognitive and neurosensorial impairment in elderly (excluding Alzheimer's disease and other dementia)”, the efficacy data were mainly provided from study publications conducted in patients with dementia (Alzheimer disease, multi-infarct dementia, vascular dementia, Parkinson disease, etc), while dementia is excluded from the scope of this referral procedure.
Estonian: Näidustuse „kroonilise patoloogilise kognitiivse ja neurosensoorse häire sümptomaatiline ravi eakatel patsientidel (välja arvatud Alzheimeri tõbi ja muu dementsus)” osas pärinesid efektiivsusandmed peamiselt publikatsioonidest uuringute kohta, mis olid läbi viidud dementsusega patsientidel
English: − Ancillary treatment of visual acuity decrease and visual field disturbances presumably of vascular origin.
Estonian: − eeldatava vaskulaarse päritoluga nägemisteravuse vähenemise ja nägemisvälja häirete täiendav ravi,
English: − Is not favourable for prophylaxis of migraine headache.
Estonian: − ei ole soodne migreeni profülaktika korral.
English: The full EPAR for Myfenax can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Myfenaxi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The European Commission granted a marketing authorisation valid throughout the EU for Myfenax on 21 February 2008.
Estonian: Euroopa Komisjon andis Myfenaxi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 21. veebruaril 2008.
English: In children aged between two and 18 years, the dose of Myfenax is calculated depending on height and weight.
Estonian: 2-18-aastastel lastel arvutatakse Myfenaxi annus olenevalt nende pikkusest ja kaalust.
English: For more information about treatment with Myfenax, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Myfenaxiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Myfenax treatment should be initiated and maintained by a qualified transplant specialist.
Estonian: Ravi Myfenaxiga peab alustama ja läbi viima pädev elundisiirdamise eriarst.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Myfenax.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: This is a summary of the European public assessment report (EPAR) for Myfenax.
Estonian: See on ravimi Myfenax Euroopa avaliku hindamisaruande kokkuvõte.
English: The Committee recommended that Myfenax be given marketing authorisation.
Estonian: Komitee soovitas anda Myfenaxi müügiloa.
English: Because Myfenax is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Myfenax on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: Other information about Myfenax
Estonian: Muu teave Myfenaxi kohta
English: For liver transplants in adults, mycophenolate mofetil should be given as an infusion (drip into a vein) for the first four days after the transplant, before the patient is switched to 1.5 g Myfenax twice a day as soon as it can be tolerated.
Estonian: Maksa siirdamise korral täiskasvanutele manustatakse mükofenolaatmofetiili infusioonina (tilgutatakse veeni) esimesel neljal päeval pärast siirdamist ning seejärel 1,5 g Myfenaxi kaks korda ööpäevas, niipea kui patsient seda annust talub.
English: Myfenax mycophenolate mofetil
Estonian: Myfenax mükofenolaatmofetiil
English: Therefore, the CHMP's view was that, as for CellCept, the benefit outweighs the identified risk.
Estonian: Seetõttu arvas inimravimite komitee, et nagu CellCepti korral, ületab Myfenaxi kasulikkus sellega kaasnevad riskid.
English: This means that Myfenax is similar to a ‘reference medicine' already authorised in the European Union (EU) called CellCept.
Estonian: See tähendab, et Myfenax on sarnane võrdlusravimiga CellCept, millel juba on Euroopa Liidus müügiluba.
English: What is Myfenax?
Estonian: Mis on Myfenax?
English: The CHMP concluded that, in accordance with EU requirements, Myfenax has been shown to have comparable quality and to be bioequivalent to CellCept.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Myfenax võrdväärne kvaliteet ja bioekvivalentsus ravimiga CellCept.
English: Because Myfenax is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, CellCept.
Estonian: Et Myfenax on geneeriline ravim, piirdusid patsiendiuuringud katsetega, milles näidati selle bioekvivalentsust võrdlusravimiga CellCept.
English: Why has Myfenax been approved?
Estonian: Miks Myfenax heaks kiideti?
English: The way that Myfenax should be given and the dose depend on the type of organ transplant and the patient's age and size.
Estonian: Myfenaxi manustamisviis ja annus sõltuvad siiratud elundist ning patsiendi vanusest, pikkusest ja kaalust.
English: Myfenax is a ‘generic medicine'.
Estonian: Myfenax on geneeriline ravim.
English: Myfenax is a medicine containing the active substance mycophenolate mofetil.
Estonian: Myfenax on ravim, mis sisaldab toimeainena mükofenolaatmofetiili.
English: By preventing the production of new DNA, Myfenax reduces the rate at which the lymphocytes multiply.
Estonian: Uue DNA moodustumist pärssides aeglustab Myfenax lümfotsüütide paljunemist.
English: The active substance in Myfenax, mycophenolate mofetil, is an immunosuppressive medicine.
Estonian: Myfenaxi toimeaine mükofenolaatmofetiil on immunosupressant.
English: What are the benefits and risks of Myfenax?
Estonian: Milles seisneb Myfenaxi kasulikkus ja mis riskid ravimiga kaasnevad?
English: How does Myfenax work?
Estonian: Kuidas Myfenax toimib?
English: Myfenax is used to prevent the body from rejecting a transplanted kidney, heart or liver.
Estonian: Myfenaxi kasutatakse siiratud neeru, südame või maksa äratõukereaktsiooni ennetamiseks.
English: How is Myfenax used?
Estonian: Kuidas Myfenaxi kasutatakse?
English: What is Myfenax used for?
Estonian: Milleks Myfenaxi kasutatakse?
English: How has Myfenax been studied?
Estonian: Kuidas Myfenaxi uuriti?
English: The referral started on 15 May 2013.
Estonian: Esildismenetlus algas 15. mail 2013.
English: Written explanations were provided by some of the applicants and marketing authorisation holders by 30 September 2013 and 3 February 2014.
Estonian: Mõned taotlejad ja müügiloa hoidjad esitasid kirjalikud märkused 30. septembriks 2013 ja 3. veebruariks 2014.
English: The Committee appointed C. Muñoz Madero as rapporteur and M. Holzhauser-Alberti as co-rapporteur.
Estonian: Komitee määras hindajaks C. Muñoz Madero ja kaashindajaks M. Holzhauser-Alberti.
English: The CVMP was also requested to consider what withdrawal periods should be applied to the concerned products for each target species.
Estonian: Veterinaarravimite komiteel paluti kaaluda ka seda, mis keeluaegu kohaldada asjaomaste ravimite suhtes igal sihtliigil.
English: The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II together with the amendments in the summaries of product characteristics, labelling and package leaflets in Annex III.
Estonian: Asjaomased raviminimetused on esitatud I lisas, teaduslikud järeldused II lisas ning muudetud ravimi omaduste kokkuvõte, märgistus ja pakendi infoleht III lisas.
English: The CVMP was requested to consider what indications, dosage regimens and durations of treatments should be applied for the products concerned in order to ensure efficacy and target animal safety and to minimise the development of antimicrobial resistance, taking into account the available data.
Estonian: Veterinaarravimite komiteel paluti olemasolevaid andmeid arvesse võttes kaaluda, milliseid näidustusi, annustamist ja ravi kestust tuleks asjaomaste ravimite suhtes kohaldada, et tagada efektiivsus ja sihtlooma ohutus ning vähendada haigustekitajate resistentsuse teket.
English: On 22 April 2013, Spain presented to the Agency a referral notification under Article 35 of Directive 2011/82/EC, regarding Baytril 2.5% injectable, Baytril 5% injectable, Baytril 10% injectable and associated names, and related veterinary medicinal products.
Estonian: 22. aprillil 2013 tegi Hispaania Euroopa Ravimiametile direktiivi 2001/82/EÜ artikli 35 kohase esildise ravimite Baytril 2,5% süstelahus, Baytril 5% süstelahus, Baytril 10% süstelahus ja sarnaste nimetuste ning seonduvate veterinaarravimite kohta.
English: Therefore, on 9 April 2014 the Committee adopted by majority a positive opinion, recommending variations to the terms of the marketing authorisations for Baytril 2.5% injectable, Baytril 5% injectable, Baytril 10% injectable and associated names, and related veterinary medicinal products.
Estonian: Seega võttis komitee 9. aprillil 2014 häälteenamusega vastu positiivse arvamuse, milles soovitas muuta ravimite Baytril 2,5% süstelahus, Baytril 5% süstelahus, Baytril 10% süstelahus ja sarnaste nimetuste ning seonduvate veterinaarravimite müügilubade tingimusi.
English: Opinion following an Article 350F referral for Baytril 2.5% injectable, Baytril 5% injectable, Baytril 10% injectable and associated names, and related veterinary medicinal products
Estonian: Arvamus pärast artikli 350F kohast esildist ravimite Baytril 2,5% süstelahus, Baytril 5% süstelahus, Baytril 10% süstelahus ja sarnaste nimetuste ning seonduvate veterinaarravimite kohta
English: Opinion following an Article 351 referral for Baytril 2.5% injectable, Baytril 5% injectable, Baytril 10% injectable and associated names, and related veterinary medicinal products
Estonian: kohast esildist ravimite Baytril 2,5% süstelahus, Baytril 5% süstelahus, Baytril 10% süstelahus ja sarnaste nimetuste ning seonduvate veterinaarravimite kohta
English: 8 May 2018
Estonian: 8. mai 2018
English: The European Commission issued a decision on 8 May 2018.
Estonian: Euroopa Komisjoni tegi otsuse 8. mail 2018.
English: Outcome of a procedure under Article 34 of Directive 2001/82/EC (EMEA/V/A/122)
Estonian: Direktiivi 2001/82/EÜ artikli 34 kohase esildismenetluse (EMEA/V/A/122) tulemused
English: Girolan (and its associated name Apralan) is marketed in Denmark, France, Germany, Ireland, Italy, The Netherlands, Portugal, Spain and the United Kingdom.
Estonian: Girolani (ja sarnast nimetust Apralani) turustatakse Hispaanias, Iirimaal, Itaalias, Madalmaades, Portugalis, Prantsusmaal, Saksamaal, Taanis ja Ühendkuningriigis.
English: Girolan is authorised in the EU via national procedures.
Estonian: Girolan on Euroopa Liidus saanud müügiloa riiklike menetlustega.
English: The amended product information is available on the 'All documents' tab.
Estonian: Muudetud ravimiteave on kõigi dokumentide vahekaardil („All documents“).
English: Questions and answers on Girolan and its associated name Apralan EMA/295529/2018
Estonian: Girolani ja sarnase nimetuse Apralani teave EMA/295529/2018
English: Why was Girolan and its associated name Apralan reviewed?
Estonian: Miks Girolani ja sarnase nimetuse Apralani ravimiteave uuesti läbi vaadati?
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that there is a need to harmonise the product information [summary of product characteristics (SPC), labelling and package leaflet] for the aforementioned product in the European Union (EU).
Estonian: EMA veterinaarravimite komitee järeldas, et eespool nimetatud ravimite ravimiteave (ravimi omaduste kokkuvõte, märgistus ja pakendi infoleht) tuleb Euroopa Liidus ühtlustada.
English: Spain noted that there are divergences across Member States in the way the veterinary medicinal product can be used, as seen in the differences in the product information in the countries where Girolan (and its associated name Apralan) is marketed.
Estonian: Hispaania märkis, et veterinaarravimite näidustused on liikmesriigiti erinevad, nagu nähtub Girolani (ja sarnast nimetust Apralani) turustavate riikide ravimiteabest.
English: On 15 February 2018, the European Medicines Agency (the Agency) completed a review of Girolan and its associated name, Apralan.
Estonian: 15. veebruaril 2018 lõpetas Euroopa Ravimiamet (EMA) Girolani ja sarnase nimetuse Apralani ravimiteabe läbivaatamise.
English: Girolan is a veterinary medicinal product available as a powder for use in drinking water/milk containing apramycin sulfate as the active substance.
Estonian: Girolan on veterinaarravim, mida turustatakse joogivees/piimas kasutatava pulbrina ja mis sisaldab toimeainena apramütsiinsulfaati.
English: Based on the evaluation of the currently-available data, the CVMP concluded by majority that the product information for Girolan and its associated name Apralan should be harmonised across the EU.
Estonian: Tuginedes praegu kättesaadavatele andmetele, järeldas veterinaarravimite komitee häälteenamusega, et Girolani ja sarnase nimetuse Apralani ravimiteave tuleb Euroopa Liidus ühtlustada.
English: enterica serovar Dublin (Salmonella Dublin) in pre-ruminant calves; treatment of colibacillosis caused by Escherichia coli in chickens and treatment and metaphylaxis of bacterial enteritis caused by Escherichia coli in rabbits.
Estonian: enterica serovar Dublini (Salmonella Dublin) põhjustatud kliiniliste puhangute korral mittemäletsevatel vasikatel; Escherichia coli põhjustatud kolibatsilloosi raviks kanadel ning Escherichia coli põhjustatud bakteriaalse enteriidi raviks ja metafülaktikaks küülikutel.
English: What is Girolan and its associated name Apralan?
Estonian: Mis on Girolan ja sarnane nimetus Apralan?
English: Girolan is indicated for the treatment of bacterial enteritis caused by Escherichia coli in pigs; treatment of bacterial enteritis caused by Escherichia coli and clinical outbreaks due to Salmonella enterica subsp.
Estonian: Girolan on näidustatud Escherichia coli põhjustatud bakteriaalse enteriidi raviks sigadel; Escherichia coli põhjustatud bakteriaalse enteriidi raviks ja Salmonella enterica subsp.
English: Apramycin is a broad-spectrum aminocyclitol antibiotic produced by a strain of Streptomyces tenebrarius.
Estonian: Apramütsiin on laia toimespektriga aminotsüklitoolantibiootikum, mis tekib bakteri Streptomyces tenebrarius teatud tüves.
English: On 24 June 2016, Spain referred the matter to the CVMP in order to harmonise the product information for Girolan (and its associated name Apralan) in the EU.
Estonian: 24. juunil 2016 tegi Hispaania veterinaarravimite komiteele esildise Girolani (ja sarnase nimetuse Apralani) ravimiteabe ühtlustamiseks Euroopa Liidus.
English: Questions and answers on Girolan and its associated name Apralan
Estonian: Girolani ja sarnase nimetuse Apralani teave
English: The absolute bioavailability is 76%.
Estonian: Absoluutne biosaadavus on 76 %.
English: • Information regarding the need for evaluation on tuberculosis (TB)
Estonian: • Teave tuberkuloosi (TB) hindamise vajaduse kohta
English: Caregivers and healthcare professionals only:
Estonian: Ainult hooldajatele ja tervishoiutöötajatele:
English: Erelzi can be taken with or without food or drink.
Estonian: Erelzit võib võtta koos toidu ja joogiga või ilma.
English: For the safety and health of you and others, needles and used syringes must never be re-used.
Estonian: Teie ja teiste ohutuse ja tervise huvides ei tohi nõelu ja kasutatud süstleid kunagi uuesti kasutada.
English: --------Etanercept------
Estonian: -------Etanertsept-----
English: • Patient´s name, Doctor´s name and phone number
Estonian: • Patsiendi nimi, arsti nimi ja telefoninumber
English: DO NOT USE
Estonian: MITTE KASUTADA
English: • Educational materials will be constantly updated for further improvements
Estonian: • Õppematerjale tuleb edasiste täienduste huvides pidevalt uuendada
English: Important safety information
Estonian: Oluline ohutusalane teave
English: Frequency Not Known (Cannot be Estimated from Available Data)
Estonian: Teadmata (ei saa hinnata olemasolevate andmete alusel)
English: • Never try to re-use your pen.
Estonian: • Ärge kunagi proovige uuesti kasutada pen-süstlit.
English: • The pen can now be removed.
Estonian: • Pen-süstli võib nüüd eemaldada.
English: Important safety checks before you inject:
Estonian: Oluline ohutuse kontroll enne süstimist:
English: Erelzi is also prescribed for the treatment of the following diseases in children and adolescents:
Estonian: Erelzit määratakse ka järgmiste haiguste raviks lastel ja noorukitel:
English: Responses of patients with psoriasis in studies 2, 3 and 4
Estonian: Psoriaasiga patsientide ravivastus uuringutes 2, 3 ja 4
English: Contact your doctor if the green indicator is not visible.
Estonian: Pöörduge arsti poole, kui rohelist märki ei ole näha.
English: Hold the syringe finger flange as shown.
Estonian: Hoidke süstli sõrmeäärikut, nagu näidatud.
English: It is important not to try to inject yourself until you have been trained by your doctor, nurse or pharmacist.
Estonian: On oluline, et te ei prooviks ennast süstida enne, kui teid on õpetanud arst, meditsiiniõde või apteeker.
English: The syringe cannot be re-used.
Estonian: Süstlit ei saa uuesti kasutada.
English: During the injection you will hear 2 loud clicks.
Estonian: Süstimise ajal kuulete 2 valjut plõksatust.
English: • Sandoz staff will be trained on the correct use of Erelzi in order to support HCPs in case of questions
Estonian: • Sandoz'i personali koolitatakse Erelzi õige kasutamise alal, et tervishoiutöötajaid küsimuste korral abistada